03-06-07

Total Number of Pages in This Submission

0019240.00596US1

PTO/SB/21 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number 10/809,089-Conf. #7653 Filing Date **TRANSMITTAL** March 25, 2004 First Named Inventor **FORM** Andrew R. MARKS Art Unit **Examiner Name** Not Yet Assigned (to be used for all correspondence after initial filing) Attorney Docket Number

ENCLOSURES (Check all that apply)							
		C = 3001120 (Ollook all ti	.a. appi				
Fee Transmitt	tal Form	Drawing(s)		After Allowance Communication to TC			
Fee Atta	ached	Licensing-related Papers		Appeal Communication to Board of Appeals and Interferences			
Amendment/F	Reply	Petition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)			
After Fi	nai	Petition to Convert to a Provisional Application		Proprietary Information			
Affidavi	its/declaration(s)	Power of Attorney, Revocation Change of Correspondence Ac		Status Letter			
Extension of	Time Request	Terminal Disclaimer		X Other Enclosure(s) (please Identify below):			
Express Abar	ndonment Request	Request for Refund		Return Receipt Postcard Form SB08			
X Information D	isclosure Statement	CD, Number of CD(s) Certificate of Express Mai					
Certified Copy	y of Priority	Landscape Table on C	D .	·			
Reply to Miss		Remarks .					
	o Missing Parts under						
	11.32 01 1.30						
•							
	SIGNATI	JRE OF APPLICANT, ATTORN	NEY, OR	AGENT			
Firm Name V	WILMER CUTLER PICKERING HALE AND DORR LLP						
Signature	ature Janem Arne						
	Jane M. Love, Ph.D.						
Date	315 07	R	Reg. No.	42,812			

Express Mail Label No. EV 901256316 US	Dated: 3 5	5 07	_	
				

WAR O 5 7007 W

Docket No.: 0019240.00596US1 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Andrew R. Marks et al.

Confirmation No.:

7653

Application No.:

10/809,089

Art Unit:

N/A

Filed:

March 25, 2004

Examiner:

Not Yet Assigned

Title:

NOVEL ANTI-ARRYTHMIC AND HEART FAILURE DRUGS THAT

TARGET THE LEAK IN THE RYANODINE RECEPTOR (RyR2)

AND USES THEREOF

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Dear Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants bring to the attention of the Examiner the documents listed on the attached Form PTO SB-08. Copies of the documents listed are not submitted herewith. These documents were previously cited by or submitted to the United States Patent and Trademark Office in U.S. Patent Application No. 10/288,606, filed November 5, 2002 and is relied upon in this application for an earlier filing date under 35 U.S.C. 120.

This Information Disclosure Statement is being filed prior to the mailing date of a first Office Action on the merits. No fee is required.

Application No.: 10/809,089 Docket No.: 0019240.00596US1

Applicants request that the Examiner initial and return a copy of the enclosed Form PTO SB-08 with the next communication.

Dated


3/5/07

Respectfully submitted,

Jane M. Love, Ph. D.

Registration No.: 42,812 Attorney for Applicant(s)

Wilmer Cutler Pickering Hale and Dorr LLP 399 Park Avenue New York, New York 10022 (212) 230-8800 (telephone) (212) 230-8888 (facsimile)





Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 9

to respond to a collection of inf	o respond to a collection of information unless it contains a valid OMB control number.					
Complete if Known						
Application Number	10/809,089-Conf. #7653					
Filing Date	March 25, 2004					
First Named Inventor	Andrew R. MARKS					
Art Unit	N/A					
Examiner Name	Not Yet Assigned					
Attorney Docket Number	0019240.00596US1					

	U.S. PATENT DOCUMENTS								
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where				
Initials*	No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear				
	AA*	US-20050213426-A1	09-29-2005						
	AB*	US-5,457,182	10-10-1995						
	AC*	US-5,461,047		Hansen, Jr. et al.					
	AD*	US-6,313,113		Lohray et al.					
	AE*	US-5,153,184	10-06-1992	Reifschneider et al.					
	AF*	US-6,683,083	01-27-2004						
	AG*	US-6,977,252	12-20-2005	· · · · · · · · · · · · · · · · · · ·					
	AH*	US-6,649,366-A1	11-18-2003	Chubinskaya et al.					
	AI*		04-11-2002	Schuh					
	AJ*	US-20020052358-A1	05-02-2002	Chubinskaya et al.					
	AK*	US-20030220310-A1	11-27-2003	Schuh					
	AL*	US-20030220312-A1	11-27-2003	Schuh					
	AM*	US-20030055027-A1	03-20-2003						
	AN*	US-20040053919-A1	03-18-2004	Chubinskaya et al.					
	AO*	US-20020132001-A1	09-19-2002	Garthwaite et al.					
	AP*			Garthwaite et al.					
	AQ*	US-20070010571-A1	01-11-2007	Garvey et al.					
	AR*	US-20060135506-A1	06-22-2006	Stephenson et al.					
	AS*	US-20060189603-A1	08-24-2006	Garvey et al.					
	AT*	US-20050009733-A1	01-13-2005	Stephenson et al.					
	AU*	US-20050059655-A1		Garvey et al.					
	AV*	US-20050159403-A1		Stephenson et al.					
	AW*	US-20040229803-A1	11-18-2004	Stephenson et al.					
	AX*	US-20030044845-A1	03-06-2003	Jenkins et al.					
	AY*	US-6,830,896-A1	12-14-2004	Kaneko et al.					
	AZ*	US-6,906,072	06-14-2005	Yamamoto et al.					
	AA1*	US-5,767,247	06-16-1998						
	AB1*	US-5,304,558	04-19-1994	Kaneko et al.					
	AC1*	US-20060084658-A1	04-20-2006	Yamamoto et al.					
	AD1*	US-20040220193-A1	11-04-2004						
	AE1*	US-20030064406-A1		Kaneko et al.	_				
		US-20030124637-A1	07-03-2003	Kaneko et al.					
	AG1*	US-6,812,252-A1	11-02-2004						
		US-6,897,295	05-24-2005	Nagata et al.					
	Al1*	US-6,962,926-A1	11-08-2005	Laborde et al.					
	AJ1*	US-6,998,469-A1	02-14-2006	Tandon et al.					
		US-6,271,353	08-07-2001	Nakamura et al.					
			07-03-2001	Tokino et al.					
		US-6,316,485	11-13-2001	Nakamura et al.					
		US-6,348,334	02-19-2002	Nagata et al.					
		US-5,753,649	05-19-1998	Tahara et al.					
	AP1*	US-6,130,060	10-10-2000	Nakamura, deceased et al.					
		US-6,184,352	02-06-2001	Nakamura et al.					
		US-5,179,125		Mimura et al.					
	AS1*	US-5,210,266	05-11-1993	Mimura et al.					

Examiner	 Date	-
Signature	Considered	

Sub	ostitute for form 1449/PTO			Complete if Known		
				Application Number	10/809,089-Conf. #7653	
11	NFORMATION	N DI	SCLOSURE	Filing Date	March 25, 2004	
STATEMENT BY APPLICANT				First Named Inventor	Andrew R. MARKS	
				Art Unit	N/A	
	(Use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	2	of	9	Attorney Docket Number	0019240.00596US1	

				1	1
	•	US-5,387,684	02-07-1995		
		US-5,478,832	12-26-1995		
	AV1*	US-5,523,410	06-04-1996	Kagara et al.	
	AW1	US-5,593,988	01-14-1997	Tahara et al.	
	AX1*	US-5,665,881	09-09-1997	Inoue et al.	
		US-4,567,254	01-28-1986	Kataoka et al.	
	AZ1*	US-4,658,055	04-14-1987	Onuki et al.	
	AA2*	US-4,849,535	07-18-1989	Naora et al.	
	AB2*	US-20050171196-A1	08-04-2005	Fujii et al.	
	AC2*	US-20030186885-A1	10-02-2003	Tandon et al.	
	AD2*			Laborde et al.	
	AE2*	US-20050074762-A1	04-07-2005	Nakamura et al.	
	AF2*	US-20030191323-A1	10-09-2003	Ikawa et al.	
	AG2*	US-20030181764-A1	09-25-2003	Ikawa et al.	
	AH2*	US-7,135,466-A1	11-14-2006	Sakai et al.	
	Al2*	US-6,750,255-A1	06-15-2004	Sakai et al.	
	AJ2*	US-6,821,987-A1	11-23-2004	Kubo et al.	
	AK2*	US-6,939,895-A1	09-06-2005	Sakai et al.	
	AL2*	US-6,362,231	03-26-2002	Sakai et al.	
Î	AM2*	US-6,500,816	12-31-2002	Ekimoto et al.	
	AN2*	US-20060258701-A1	11-16-2006	Mitsuya et al.	
	AO2*	US-20060211717-A1	09-21-2006	Sakai et al.	
	AP2*	US-20040132727-A1	07-08-2004	Sakai et al.	
	AQ2*	US-20040229876-A1	11-18-2004	Kubo et al.	
	AR2*	US-20020107406-A1	08-08-2002	Sakai et al.	
		US-20030087907-A1	05-08-2003		
	AT2*	US-20030176485-A1	09-18-2003	Sakai et al.	
	AU2*	US-20030144526-A1	07-31-2003	Sakai et al.	
	AV2*	US-7,163,952-A1	01-16-2007		
	AW2	US-6,753,346-A1	06-22-2004	Shinkai et al.	
	AX2*	US-6,803,039-A1	10-12-2004	Tsuji et al.	
		US-6,869,975-A1	03-22-2005	· · · · · · · · · · · · · · · · · · ·	
		US-7,030,225	04-18-2006	Tamatani et al.	
	AA3*	US-7,045,615-A1		Tamatani et al.	
	AB3*	US-7,112,655	09-26-2006		
	AC3*	US-6,235,730	05-22-2001	Sato et al.	
		US-6,426,365	07-30-2002	Shinkai et al.	
		US-6,410,561	06-25-2002		
	AF3*	US-6,583,157-A1	06-24-2003		
	AG3*	US-6,562,618	05-13-2003	Tamatani et al.	
		US-6,562,828	05-13-2003	Katoh et al.	
		US-5,719,155	02-17-1998	Cho et al.	
	AJ3*	US-5,750,696	05-12-1998	Shibata et al.	
	AK3*	US-5,824,862		Hiyoshi et al.	
	AL3*	US-5,807,850		Nakamura et al.	
		US-5,792,655		Watanabe et al.	
	AN3	US-5,142,647	08-25-1992	Nakagawa et al.	

Examiner	 Date		
Signature	Consi	dered	

Complete if Known Substitute for form 1449/PTO Application Number 10/809,089-Conf. #7653 **INFORMATION DISCLOSURE** March 25, 2004 Filing Date STATEMENT BY APPLICANT Andrew R. MARKS First Named Inventor Art Unit N/A (Use as many sheets as necessary) Not Yet Assigned Examiner Name Sheet 3 of 9 0019240.00596US1 Attorney Docket Number

AG3" US-5,214,056 O5-25-1993 Haruta et al.	A00*	LIC E 014 OEC	05 05 1000	I louve et el	
AG2 US-5,304,380					
AR3' US-6,260,286					
AS3' US-5,332,734 07-26-1994 Kobayashi et al.				 	
AT3' US-5,354,758 10-11-1994 Lawson et al					
AU3" US-5,476,780					
AV3' US-4,845,065					
AX3' US-4,845,065 07-04-1989 Sugimori et al. AX3' US-4,841,055 06-20-1989 Matsumoto et al. AZ3' US-20500187221-A1 08-25-2005 Matsuda et al. AA4' US-20050187221-A1 12-15-2005 DeGraffenreid et al. AA4' US-2005003589-A1 12-15-2005 DeGraffenreid et al. AB4' US-2006003589-A1 02-17-2005 Akiyama AC4' US-20060035882-A1 02-18-2006 Koga et al. AD4' US-20060035882-A1 02-18-2006 Kawasaki et al. AE4' US-2006003585-A1 02-09-2006 Shinkai et al. AF4' US-20060059575-A1 03-16-2006 Kusunoki et al. AF4' US-20060059575-A1 03-16-2006 Kusunoki et al. AF4' US-20060223133-A1 10-05-2006 Kusunoki et al. AF4' US-20060225731-A1 09-14-2006 Kodama et al. AF4' US-20060122181-A1 06-08-2006 Ikemoto et al. AF4' US-20060122181-A1 06-08-2006 Ikemoto et al. AF4' US-2006070705-A1 11-30-2006 Vonemori et al. AF4' US-2004073012-A1 04-15-2004 Tamatani et al. AF4' US-2004017302658-A1 07-08-2004 Tamatani et al. AF4' US-2004017302658-A1 07-08-2004 Tamatani et al. AF4' US-20040174084-A1 06-24-2004 Tamatani et al. AF4' US-20040174084-A1 06-22-2004 Tamatani et al. AF4' US-20040175034-A1 06-22-2004 Tamatani et al. AF4' US-20040175034-A1 09-02-2004 Tamatani et al. AF4' US-200401751720-A1 09-16-2004 Tamatani et al. AF4' US-200401751720-A1 08-05-2004 Tamatani et al. AF4' US-20040151768-A1 08-05-2004 Tamatani et al. AF4' US-20040151769-A1 08-05-2004 Tamatani et al. AF4' US-20040151769-A1 08-05-2004 Tamatani et al. AF4' US-20040151699-A1 08-05-2004 Tamatani et al. AF5' US-20040125995-A1 11-18-2004 Sinkai et al. AF5' US-2004022978-A1 11-18-2004 Tamatani et al. AF5' US-2004022978-A1 11-18-2004 Tamatani et al. AF5' US-2005005068-A1 03-31-2005 Okamoto AF5' US-2005005181-A1 03-31-2005 Okamoto AF5' US-200501564-A1 10-24-2002 Tamatani et					
AX3' US-4,845,065 07-04-1989 Sugimori et al. AY3' US-4,841,055 06-20-1989 Matsumoto et al. AZ3' US-20050187221-A1 08-25-2005 Matsuda et al. AA4' US-20050035839-A1 02-17-2005 Akiyama AC4' US-20060035839-A1 02-17-2005 Akiyama AC4' US-20060013682-A1 02-16-2006 Koga et al. AD4' US-20060013682-A1 01-19-2006 Kawasaki et al. AE4' US-2006003655-A1 02-09-2006 Sininkai et al. AE4' US-2006002575-A1 03-16-2006 Kusunoki et al. AF4' US-20060023137-A1 10-05-2006 Tamatani et al. AH4' US-2006022313-A1 10-05-2006 Kodama et al. AJ4' US-2006022313-A1 10-05-2006 Kodama et al. AJ4' US-2006027075-A1 11-30-2006 Vonemori et al. AJ4' US-200607705-A1 11-30-2006 Vonemori et al. AK4' US-20040073012-A1 04-15-2004 Tamatani et al. AX4' US-20040132658-A1 07-08-2004 Tamatani et al. AX4' US-20040132658-A1 07-08-2004 Tamatani et al. AX4' US-2004013052-A1 09-16-2004 Mizutani et al. AX4' US-20040171613-A1 09-02-2004 Mizutani et al. AX4' US-20040151718-A1 09-02-2004 Mizutani et al. AX4' US-20040151718-A1 09-02-2004 Tamatani et al. AX4' US-20040151718-A1 08-05-2004 Tamatani et al. AX4' US-20040151718-A1 08-05-2004 Tamatani et al. AX4' US-20040146991-A1 10-21-2004 Fox et al. AX4' US-2004012698-A1 11-18-2004 Tamatani et al. AX4' US-20040146991-A1 10-21-2004 Tamatani et al. AX5' US-20040146901-A1 10-21-2004 Tamatani et al. AX6' US-20040146901-A1 10-21-2004 Tamatani et al. AX6' US-20040146901-A1 10-21-2004 Tamatani et al. AX6' US-20040150505-A1 11-18-2004 Tamatani et al. AX6					
AV3' US-4,841,055	*				
AZ3* US-20050187221-A1 08-25-2005 Matsuda et al.					
AA4* US-20050277649-A1		, , , , , , , , , , , , , , , , , , , ,	· · · · · · · · · · · · · · · · · · ·		
AB4" US-20050035939-A1 02-16-2006 Koga et al.				 	
ACA' US-20060035862-A1 02-16-2006 Koga et al.					
AD4					
AE4* US-20060030565-A1 02-09-2006 Shinkai et al.					
AF4* US-2006025975-A1 03-16-2006 Kusunoki et al.					
AG4* US-20060223133-A1 10-05-2006 Tamatani et al. AIA* US-20060205731-A1 09-14-2006 Kodama et al. AIA* US-20060270705-A1 11-30-2006 Ikemoto et al. AIA* US-20060270705-A1 11-30-2006 Vonemori et al. AIA* US-20040073012-A1 04-15-2004 Tamatani et al. AIA* US-20040073012-A1 04-15-2004 Tamatani et al. AIA* US-20040132658-A1 07-08-2004 Tamatani et al. AIA* US-20040120945-A1 06-24-2004 Tamatani et al. AIA* US-20040120945-A1 06-24-2004 Tamatani et al. AIA* US-20040180052-A1 09-16-2004 Tamatani et al. AIA* US-2004017409-A1 01-29-2004 Mizutani et al. AIA* US-2004015173-A1 09-02-2004 Imamatani et al. AIA* US-2004015173-A1 08-05-2004 Tamatani et al. AIA* US-2004015173-A1 08-05-2004 Tamatani et al. AIA* US-2004015173-A1 08-05-2004 Tamatani et al. AIA* US-20040146991-A1 07-29-2004 Tamatani et al. AIA* US-20040146991-A1 07-29-2004 Tamatani et al. AIA* US-20040146991-A1 10-21-2004 Tamatani et al. AIA* US-20040299871-A1 10-21-2004 Tamatani et al. AIA* US-20040229957-A1 11-18-2004 Tamatani et al. AIA* US-20040229970-A1 11-18-2004 Tamatani et al. AIA* US-20040229970-A1 11-18-2004 Tamatani et al. AIA* US-20040229970-A1 11-18-2004 Tamatani et al. AIA* US-2004022998-A1 11-18-2004 Tamatani et al. AIA* US-20040229970-A1 11-18-2004 Tamatani et al. AIA* US-2005002668-A1 01-27-2005 Urata et al. AIAS* US-2005002668-A1 01-27-2005 Urata et al. AIAS* US-20050059810-A1 03-17-2005 Urata et al. AIAS* US-20050156242-A1 02-22002 Tamatani					
AH4* US-20060205731-A1	AF4*	US-20060059575-A1		<u> </u>	
Al4* US-20060122181-A1 06-08-2006 Ikemoto et al.					
AJ4* US-20060270705-A1 11-30-2006 Yonemori et al.	AH4*				
AK4* US-20070010670-A1					
AL4* US-20040073012-A1					
AM4* US-20040132658-A1 07-08-2004 Tamatani et al. AN4* US-2004017409-A1 06-24-2004 Tamatani et al. AO4* US-20040017409-A1 01-29-2004 Mizutani et al. AP4* US-20040180052-A1 09-16-2004 Tsuji et al. AO4* US-20040151718-A1 09-02-2004 Iwamura et al. AR4* US-20040151718-A1 08-05-2004 Tamatani et al. AS4* US-20040151720-A1 08-05-2004 Tamatani et al. AX4* US-20040151669-A1 08-05-2004 Tamatani et al. AV4* US-20040146991-A1 07-29-2004 Tsuji et al. AV4* US-20040146506-A1 07-29-2004 Tsuji et al. AV4* US-20040146506-A1 07-29-2004 Tamatani et al. AV4* US-20040299871-A1 10-21-2004 Fox et al. AX4* US-2004022978-A1 11-18-2004 Shinkai et al. AX4* US-20040229790-A1 11-18-2004 Tezuka et al. AX4* US-2004022978-A1 11-18-2004 Tezuka et al. AX5* US-2004022978-A1 11-18-2004 Tezuka et al. AX6* US-20050020668-A1 01-27-2005 Urata et al. AX6* US-20050070545-A1 03-31-2005 Fox et al. AX6* US-20050051181-A1 03-17-2005 Maeda et al. AX6* US-20020115831-A1 03-17-2005 Okamoto AX6* US-20020115831-A1 03-17-2005 Tamatani et al. AX6* US-20020115831-A1 03-17-2005 Tamatani et al. AX6* US-20020115831-A1 08-22-2002 Tamatani et al. AX6* US-20020115831-A1 08-22-2002 Tamatani et al.	AK4*	US-20070010670-A1	01-11-2007	Hirata et al.	
AN4* US-20040120945-A1 06-24-2004 Tamatani et al. AO4* US-20040017409-A1 01-29-2004 Mizutani et al. AP4* US-20040180052-A1 09-16-2004 Tsuji et al. AQ4* US-20040171613-A1 09-02-2004 Iwamura et al. AR4* US-20040151718-A1 08-05-2004 Tamatani et al. AS4* US-20040151720-A1 08-05-2004 Tamatani et al. AS4* US-20040151669-A1 08-05-2004 Tamatani et al. AT4* US-20040151669-A1 08-05-2004 Tamatani et al. AV4* US-20040146991-A1 07-29-2004 Tsuji et al. AV4* US-20040146506-A1 07-29-2004 Tsuji et al. AV4* US-20040209871-A1 10-21-2004 Fox et al. AX4* US-20040242683-A1 12-02-2004 Urata et al. AX4* US-20040229957-A1 11-18-2004 Shinkai et al. AZ4* US-20040229987-A1 11-18-2004 Tezuka et al. AX5* US-20040229788-A1 11-18-2004 Tamatani et al. AB5* US-20040225018-A1 11-11-2004 Sunami et al. AC5* US-20050020668-A1 01-27-2005 Urata et al. AD5* US-20050070545-A1 03-31-2005 Fox et al. AF5* US-20050051181-A1 03-10-2005 Okamoto AG5* US-20020156242-A1 10-24-2002 Tamatani et al. AH5* US-20020156242-A1 10-24-2002 Tamatani et al.					
AO4* US-20040017409-A1 01-29-2004 Mizutani et al. AP4* US-20040180052-A1 09-16-2004 Tsuji et al. AQ4* US-20040171613-A1 09-02-2004 Iwamura et al. AR4* US-20040151718-A1 08-05-2004 Tamatani et al. AS4* US-20040151720-A1 08-05-2004 Tamatani et al. AT4* US-20040151669-A1 08-05-2004 Tamatani et al. AU4* US-20040151669-A1 07-29-2004 Tsuji et al. AV4* US-20040146991-A1 07-29-2004 Tsuji et al. AV4* US-20040146506-A1 07-29-2004 Tsuji et al. AV4* US-20040209871-A1 10-21-2004 Fox et al. AX4* US-20040242683-A1 12-02-2004 Urata et al. AY4* US-20040229957-A1 11-18-2004 Shinkai et al. AZ4* US-20040229790-A1 11-18-2004 Tzuka et al. AA5* US-20040229788-A1 11-18-2004 Tzuka et al. AA5* US-20040229788-A1 11-18-2004 Tzuka et al. AB5* US-2005002668-A1 01-27-2005 Urata et al. AC5* US-20050070545-A1 03-31-2005 Fox et al. AE5* US-20050059810-A1 03-17-2005 Maeda et al. AF5* US-20050051181-A1 03-10-2005 Okamoto AG5* US-20020156242-A1 10-24-2002 Tamatani et al.	AM4*	US-20040132658-A1			
AP4* US-20040180052-A1 09-16-2004 Tsuji et al. AQ4* US-20040171613-A1 09-02-2004 Iwamura et al. AR4* US-20040151718-A1 08-05-2004 Tamatani et al. AS4* US-20040151720-A1 08-05-2004 Tamatani et al. AT4* US-20040151669-A1 08-05-2004 Tamatani et al. AT4* US-20040146991-A1 07-29-2004 Tsuji et al. AU4* US-20040146506-A1 07-29-2004 Tsuji et al. AV4* US-20040146506-A1 07-29-2004 Tamatani et al. AV4* US-20040209871-A1 10-21-2004 Fox et al. AX4* US-20040242683-A1 12-02-2004 Urata et al. AY4* US-20040229957-A1 11-18-2004 Shinkai et al. AZ4* US-20040229790-A1 11-18-2004 Tezuka et al. AZ5* US-20040229788-A1 11-18-2004 Tamatani et al. AB5* US-20040225018-A1 11-11-2004 Sunami et al. AC5* US-20050020668-A1 01-27-2005 Urata et al. AD5* US-20050070545-A1 03-31-2005 Fox et al. AE5* US-20050051181-A1 03-10-2005 Okamoto AG5* US-20020115831-A1 08-22-2002 Tamatani et al. AH5* US-20020156242-A1 10-24-2002 Tamatani et al.	AN4*	US-20040120945-A1			
AQ4* US-20040171613-A1 09-02-2004 Iwamura et al. AR4* US-20040151718-A1 08-05-2004 Tamatani et al. AS4* US-20040151720-A1 08-05-2004 Tamatani et al. AT4* US-20040151669-A1 08-05-2004 Tamatani et al. AU4* US-20040146991-A1 07-29-2004 Tsuji et al. AV4* US-20040146506-A1 07-29-2004 Tamatani et al. AW4 US-20040209871-A1 10-21-2004 Fox et al. AX4* US-20040242683-A1 12-02-2004 Urata et al. AY4* US-20040229957-A1 11-18-2004 Shinkai et al. AZ4* US-20040229998-A1 11-18-2004 Tezuka et al. AZ4* US-20040229790-A1 11-18-2004 Tezuka et al. AA5* US-20040229788-A1 11-18-2004 Tamatani et al. AB5* US-20040225018-A1 11-11-2004 Sunami et al. AC5* US-20050020668-A1 01-27-2005 Urata et al. AB5* US-20050070545-A1 03-31-2005 Fox et al. AE5* US-20050051181-A1 03-17-2005 Maeda et al. AF5* US-20020115831-A1 08-22-2002 Tamatani et al. AH5* US-20020156242-A1 10-24-2002 Tamatani et al. AH5* US-20020156242-A1 10-24-2002 Tamatani et al.					
AR4* US-20040151718-A1 08-05-2004 Tamatani et al. AS4* US-20040151720-A1 08-05-2004 Tamatani et al. AT4* US-20040151669-A1 08-05-2004 Tamatani et al. AU4* US-20040146991-A1 07-29-2004 Tsuji et al. AV4* US-20040146506-A1 07-29-2004 Tamatani et al. AW4 US-20040209871-A1 10-21-2004 Fox et al. AX4* US-20040242683-A1 12-02-2004 Urata et al. AY4* US-20040229957-A1 11-18-2004 Shinkai et al. AZ4* US-2004022978-A1 11-18-2004 Tezuka et al. AZ4* US-20040229788-A1 11-18-2004 Tamatani et al. AA5* US-20040225018-A1 11-11-2004 Sunami et al. AC5* US-20050020668-A1 01-27-2005 Urata et al. AD5* US-20050070545-A1 03-31-2005 Fox et al. AF5* US-20050051181-A1 03-10-2005 Okamoto AG5* US-20020115831-A1 08-22-2002 Tamatani et al. AH5* US-20020156242-A1 10-24-2002 Tamatani et al.					
AS4* US-20040151720-A1 08-05-2004 Tamatani et al. AT4* US-20040151669-A1 08-05-2004 Tamatani et al. AU4* US-20040146991-A1 07-29-2004 Tsuji et al. AV4* US-20040146506-A1 07-29-2004 Tamatani et al. AW4 US-20040209871-A1 10-21-2004 Fox et al. AX4* US-20040242683-A1 12-02-2004 Urata et al. AY4* US-20040229957-A1 11-18-2004 Shinkai et al. AZ4* US-20040229790-A1 11-18-2004 Tezuka et al. AA5* US-20040229788-A1 11-18-2004 Tamatani et al. AA5* US-20040229788-A1 11-18-2004 Tamatani et al. AB5* US-20040225018-A1 11-11-2004 Sunami et al. AC5* US-20050020668-A1 01-27-2005 Urata et al. AD5* US-20050070545-A1 03-31-2005 Fox et al. AE5* US-20050059810-A1 03-17-2005 Maeda et al. AF5* US-20050051181-A1 03-10-2005 Okamoto AG5* US-20020115831-A1 08-22-2002 Tamatani et al. AH5* US-20020156242-A1 10-24-2002 Tamatani et al.					
AT4* US-20040151669-A1 08-05-2004 Tamatani et al. AU4* US-20040146991-A1 07-29-2004 Tsuji et al. AV4* US-20040146506-A1 07-29-2004 Tamatani et al. AW4 US-20040209871-A1 10-21-2004 Fox et al. AX4* US-20040242683-A1 12-02-2004 Urata et al. AY4* US-20040229957-A1 11-18-2004 Shinkai et al. AZ4* US-20040229790-A1 11-18-2004 Tezuka et al. AA5* US-20040229788-A1 11-18-2004 Tamatani et al. AA5* US-20040229788-A1 11-11-2004 Sunami et al. AB5* US-20040225018-A1 11-11-2004 Sunami et al. AC5* US-20050020668-A1 01-27-2005 Urata et al. AD5* US-20050070545-A1 03-31-2005 Fox et al. AE5* US-20050059810-A1 03-17-2005 Maeda et al. AF5* US-20050051181-A1 03-10-2005 Okamoto AG5* US-20020115831-A1 08-22-2002 Tamatani et al. AH5* US-20020156242-A1 10-24-2002 Tamatani et al.					
AU4* US-20040146991-A1 07-29-2004 Tsuji et al. AV4* US-20040146506-A1 07-29-2004 Tamatani et al. AW4 US-20040209871-A1 10-21-2004 Fox et al. AX4* US-20040242683-A1 12-02-2004 Urata et al. AY4* US-20040229957-A1 11-18-2004 Shinkai et al. AZ4* US-20040229790-A1 11-18-2004 Tezuka et al. AA5* US-20040229788-A1 11-18-2004 Tamatani et al. AB5* US-20040229788-A1 11-11-2004 Sunami et al. AB5* US-20040225018-A1 11-11-2004 Sunami et al. AC5* US-20050020668-A1 01-27-2005 Urata et al. AD5* US-20050070545-A1 03-31-2005 Fox et al. AE5* US-20050059810-A1 03-17-2005 Maeda et al. AF5* US-20050051181-A1 03-10-2005 Okamoto AG5* US-20020115831-A1 08-22-2002 Tamatani et al. AH5* US-20020156242-A1 10-24-2002 Tamatani et al.					
AV4* US-20040146506-A1 07-29-2004 Tamatani et al. AW4 US-20040209871-A1 10-21-2004 Fox et al. AX4* US-20040242683-A1 12-02-2004 Urata et al. AY4* US-20040229957-A1 11-18-2004 Shinkai et al. AZ4* US-20040229790-A1 11-18-2004 Tezuka et al. AA5* US-20040229788-A1 11-18-2004 Tamatani et al. AA5* US-20040229788-A1 11-11-2004 Sunami et al. AB5* US-20040225018-A1 11-11-2004 Sunami et al. AC5* US-20050020668-A1 01-27-2005 Urata et al. AD5* US-20050070545-A1 03-31-2005 Fox et al. AE5* US-20050059810-A1 03-17-2005 Maeda et al. AF5* US-20050051181-A1 03-10-2005 Okamoto AG5* US-20020115831-A1 08-22-2002 Tamatani et al. AH5* US-20020156242-A1 10-24-2002 Tamatani et al.	AT4*	US-20040151669-A1			
AW4 US-20040209871-A1 10-21-2004 Fox et al. AX4* US-20040242683-A1 12-02-2004 Urata et al. AY4* US-20040229957-A1 11-18-2004 Shinkai et al. AZ4* US-20040229790-A1 11-18-2004 Tezuka et al. AA5* US-20040229788-A1 11-18-2004 Tamatani et al. AB5* US-20040229788-A1 11-11-2004 Sunami et al. AB5* US-20040225018-A1 11-11-2004 Sunami et al. AC5* US-20050020668-A1 01-27-2005 Urata et al. AD5* US-20050070545-A1 03-31-2005 Fox et al. AE5* US-20050059810-A1 03-17-2005 Maeda et al. AF5* US-20050051181-A1 03-10-2005 Okamoto AG5* US-20020115831-A1 08-22-2002 Tamatani et al. AH5* US-20020156242-A1 10-24-2002 Tamatani et al.	AU4*	US-20040146991-A1			
AX4* US-20040242683-A1 12-02-2004 Urata et al. AY4* US-20040229957-A1 11-18-2004 Shinkai et al. AZ4* US-20040229790-A1 11-18-2004 Tezuka et al. AA5* US-20040229788-A1 11-18-2004 Tamatani et al. AB5* US-20040225018-A1 11-11-2004 Sunami et al. AC5* US-20050020668-A1 01-27-2005 Urata et al. AD5* US-20050070545-A1 03-31-2005 Fox et al. AE5* US-20050059810-A1 03-17-2005 Maeda et al. AF5* US-20050051181-A1 03-10-2005 Okamoto AG5* US-20020115831-A1 08-22-2002 Tamatani et al. AH5* US-20020156242-A1 10-24-2002 Tamatani et al.	AV4*	US-20040146506-A1	07-29-2004_	Tamatani et al.	
AY4* US-20040229957-A1 11-18-2004 Shinkai et al. AZ4* US-20040229790-A1 11-18-2004 Tezuka et al. AA5* US-20040229788-A1 11-18-2004 Tamatani et al. AB5* US-20040225018-A1 11-11-2004 Sunami et al. AC5* US-20050020668-A1 01-27-2005 Urata et al. AD5* US-20050070545-A1 03-31-2005 Fox et al. AE5* US-20050059810-A1 03-17-2005 Maeda et al. AF5* US-20050051181-A1 03-10-2005 Okamoto AG5* US-20020115831-A1 08-22-2002 Tamatani et al. AH5* US-20020156242-A1 10-24-2002 Tamatani et al.	AW4	US-20040209871-A1	10-21-2004	Fox et al.	
AZ4* US-20040229790-A1 11-18-2004 Tezuka et al. AA5* US-20040229788-A1 11-18-2004 Tamatani et al. AB5* US-20040225018-A1 11-11-2004 Sunami et al. AC5* US-20050020668-A1 01-27-2005 Urata et al. AD5* US-20050070545-A1 03-31-2005 Fox et al. AE5* US-20050059810-A1 03-17-2005 Maeda et al. AF5* US-20050051181-A1 03-10-2005 Okamoto AG5* US-20020115831-A1 08-22-2002 Tamatani et al. AH5* US-20020156242-A1 10-24-2002 Tamatani et al.	AX4*	US-20040242683-A1	12-02-2004	Urata et al.	
AA5* US-20040229788-A1 11-18-2004 Tamatani et al. AB5* US-20040225018-A1 11-11-2004 Sunami et al. AC5* US-20050020668-A1 01-27-2005 Urata et al. AD5* US-20050070545-A1 03-31-2005 Fox et al. AE5* US-20050059810-A1 03-17-2005 Maeda et al. AF5* US-20050051181-A1 03-10-2005 Okamoto AG5* US-20020115831-A1 08-22-2002 Tamatani et al. AH5* US-20020156242-A1 10-24-2002 Tamatani et al.	AY4*	US-20040229957-A1	11-18-2004	Shinkai et al.	
AB5* US-20040225018-A1 11-11-2004 Sunami et al. AC5* US-20050020668-A1 01-27-2005 Urata et al. AD5* US-20050070545-A1 03-31-2005 Fox et al. AE5* US-20050059810-A1 03-17-2005 Maeda et al. AF5* US-20050051181-A1 03-10-2005 Okamoto AG5* US-20020115831-A1 08-22-2002 Tamatani et al. AH5* US-20020156242-A1 10-24-2002 Tamatani et al.	AZ4*	US-20040229790-A1			
AC5* US-20050020668-A1 01-27-2005 Urata et al. AD5* US-20050070545-A1 03-31-2005 Fox et al. AE5* US-20050059810-A1 03-17-2005 Maeda et al. AF5* US-20050051181-A1 03-10-2005 Okamoto AG5* US-20020115831-A1 08-22-2002 Tamatani et al. AH5* US-20020156242-A1 10-24-2002 Tamatani et al.					
AD5* US-20050070545-A1 03-31-2005 Fox et al. AE5* US-20050059810-A1 03-17-2005 Maeda et al. AF5* US-20050051181-A1 03-10-2005 Okamoto AG5* US-20020115831-A1 08-22-2002 Tamatani et al. AH5* US-20020156242-A1 10-24-2002 Tamatani et al.	AB5*	US-20040225018-A1			
AE5* US-20050059810-A1 03-17-2005 Maeda et al. AF5* US-20050051181-A1 03-10-2005 Okamoto AG5* US-20020115831-A1 08-22-2002 Tamatani et al. AH5* US-20020156242-A1 10-24-2002 Tamatani et al.	AC5*	US-20050020668-A1	01-27-2005	Urata et al.	
AF5* US-20050051181-A1 03-10-2005 Okamoto AG5* US-20020115831-A1 08-22-2002 Tamatani et al. AH5* US-20020156242-A1 10-24-2002 Tamatani et al.	AD5*	US-20050070545-A1	03-31-2005	Fox et al.	
AG5* US-20020115831-A1 08-22-2002 Tamatani et al. AH5* US-20020156242-A1 10-24-2002 Tamatani et al.					
AG5* US-20020115831-A1 08-22-2002 Tamatani et al. AH5* US-20020156242-A1 10-24-2002 Tamatani et al.	AF5*	US-20050051181-A1	03-10-2005	Okamoto	
			08-22-2002	Tamatani et al.	
Al5* US-20020151685-A1 10-17-2002 Tamatani et al.	AH5*	US-20020156242-A1			
	Al5*	US-20020151685-A1	10-17-2002	Tamatani et al.	

Examiner	Date	
Signature	Considered	

Substitu	te for form 1449/PTO		•	Complete if Known		
				Application Number	10/809,089-Conf. #7653	
INF	ORMATIO	N DI	SCLOSURE	Filing Date	March 25, 2004	
STA	ATEMENT	BY /	APPLICANT	First Named Inventor	Andrew R. MARKS	
_				Art Unit	N/A	
	(Use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	4	of	9	Attorney Docket Number	0019240.00596US1	

ALS						
ALS US-200300232855-A1 12-18-2003 Namura et al.		AJ5*	US-20030083472-A1	05-01-2003	Tamatani et al.	
AMS US-20030092708-A1 05-15-2003 Shinkai et al.				03-20-2003	Shinkai et al.	
ANS' US-2004006099-A1 01-08-2004 Katoh et al.				12-18-2003	Iwamura et al.	
ACS US-5,508,293		AM5*	US-20030092708-A1	05-15-2003	Shinkai et al.	
APS' US-6,508,293		AN5*	US-20040006099-A1	01-08-2004	Katoh et al.	
AG5 US-6,660,837 12-09-2003 Kaibuchi et al.		AO5*	US-7,029,671	04-18-2006	Koezuka et al.	
ARS US-6,824,973-A1 11-30-2004 Tang et al.		AP5*	US-5,508,293	04-16-1996	Okawara et al.	-
ARS US-6,824,973-A1 11-30-2004 Tang et al.		AQ5*	US-6,660,837	12-09-2003	Kaibuchi et al.	
AT5' US-6,890,531 O5-10-2005 Horie et al.		AR5*	US-6,824,973-A1	11-30-2004	Tang et al.	
AU5' US-6,964,975-A1		AS5*	US-6,673,904-A1	01-06-2004	Nishikawa et al.	
AV5				05-10-2005	Horie et al.	
AX5' US-6,338,955-A1 01-15-2002				11-15-2005	Ueno et al.	
AX5' US-6,338,955-A1 01-15-2002 Oguri et al. AY5' US-6,331,595 05-21-2002 Kato et al. AZ5' US-6,632,976 10-14-2003 Tomizuka et al. AA6' US-5,780,441 07-14-1998 Higa et al. AB6' US-5,906,819 05-25-1999 Kaibuchi et al. AC6' US-6,013,499 01-11-2000 Narumiya et al. AC6' US-6,013,499 01-11-2000 Narumiya et al. AC6' US-6,111,072 08-29-2000 Narumiya et al. AE6' US-5,166,347 11-24-1992 Izawa et al. AF6' US-5,223,508 06-29-1993 Izawa et al. AF6' US-5,223,508 06-29-1993 Izawa et al. AA6' US-5,272,164 12-21-1993 Izawa et al. AH6' US-5,413,929 05-09-1995 Ishizaki et al. AI6' US-5,453,282 09-26-1995 Kanauchi et al. AI6' US-5,654,001 08-05-1997 Kanauchi et al. AK6' US-4,888,418 12-19-1998 Kawai et al. AK6' US-2,888,418 12-19-1998 Kawai et al. AK6' US-20050177884-A1 08-11-2005 Tomizuka et al. AM6' US-20050159365-A1 07-21-2005 Serizawa et al. AN6' US-20060037093-A1 02-16-2006 Tomizuka et al. AC6' US-20060037093-A1 02-16-2006 Tomizuka et al. AC6' US-20060013759-A1 01-19-2006 Kakitani et al. AC6' US-20060013755-A1 01-19-2006 Misawa et al. AC6' US-20060013755-A1 01-19-2006 Misawa et al. AC6' US-20060013755-A1 01-19-2006 Misawa et al. AC6' US-2006001375-A1 01-19-2006 Misawa et al. AC6' US-2006001375-A1 01-19-2006 Ospimura et al. AC6' US-2004007395-A1 04-15-2004 Tomizuka et al. AC7' US-20020199213-A1 12-26-2002 Tomizu		AV5*	US-7,064,194-A1	06-20-2006	Misawa et al.	
AY5" US-6,391,595 05-21-2002 Kato et al.		AW5	US-7,041,870-A1	05-09-2006	Tomizuka et al.	
AY5" US-6,391,595 05-21-2002 Kato et al.		AX5*	US-6 338 955-A1	01-15-2002	Oguri et al	
AZ5* US-6,632,976					 	
AA6* US-5,780,441 07-14-1998 Higa et al.						
AB6* US-5,906,819						
AC6* US-6,013,499	-				 	
AD6* US-6,111,072	 					
AE6* US-5,166,347						
AF6* US-5,223,508	-					
AG6* US-5,272,164 12-21-1993 Izawa et al.	1					
AH6" US-5,413,929						
Al6* US-5,453,282						
AJ6* US-5,654,001 08-05-1997 Kanauchi et al. AK6* US-4,888,418 12-19-1989 Kawai et al. AL6* US-20050177884-A1 08-11-2005 Tomizuka et al. AM6* US-20050159365-A1 07-21-2005 Serizawa et al. AN6* US-20050255546-A1 11-17-2005 Nishikawa AO6* US-20060041945-A1 02-23-2006 Robl et al. AP6* US-20060037093-A1 02-16-2006 Tomizuka et al. AQ6* US-20060026698-A1 02-02-2006 Tomizuka et al. AR6* US-20060078992-A1 04-13-2006 Misawa et al. AS6* US-200600123490-A1 06-08-2006 Kakitani et al. AT6* US-20060011375-A1 01-19-2006 Sugimoto et al. AU6* US-20060185025-A1 08-17-2006 Oshimura et al. AV6* US-20060167043-A1 07-27-2006 Iwakubo et al. AW6* US-20060217426-A1 09-28-2006 Eto et al. AX6* US-20040073957-A1 04-15-2004 Tomizuka et al. AX7* US-20040073957-A1 02-10-2005 Sato et al. AX7* US-20050032210-A1 02-10-2005 Sato et al. AC7* US-20020199213-A1 12-26-2002 Tomizuka et al.						
AK6* US-4,888,418					•	
AL6* US-20050177884-A1	<u> </u>					
AM6* US-20050159365-A1 07-21-2005 Serizawa et al. AN6* US-20050255546-A1 11-17-2005 Nishikawa AO6* US-20060041945-A1 02-23-2006 Robl et al. AP6* US-20060037093-A1 02-16-2006 Tomizuka et al. AQ6* US-20060026698-A1 02-02-2006 Tomizuka et al. AR6* US-20060078992-A1 04-13-2006 Misawa et al. AS6* US-20060123490-A1 06-08-2006 Kakitani et al. AT6* US-20060011375-A1 01-19-2006 Sugimoto et al. AU6* US-20060185025-A1 08-17-2006 Oshimura et al. AV6* US-20060167043-A1 07-27-2006 Iwakubo et al. AV6* US-20060217426-A1 09-28-2006 Eto et al. AX6* US-20060217426-A1 09-28-2006 Eto et al. AX6* US-20040073957-A1 04-15-2004 Tomizuka et al. AZ6* US-20040175814-A1 09-09-2004 Kato et al. AZ6* US-20040235162-A1 11-25-2004 Sato AB7* US-20050032210-A1 02-10-2005 Sato et al. AC7* US-20020199213-A1 12-26-2002 Tomizuka et al.	 					
AN6* US-20050255546-A1 11-17-2005 Nishikawa AO6* US-20060041945-A1 02-23-2006 Robl et al. AP6* US-20060037093-A1 02-16-2006 Tomizuka et al. AQ6* US-20060026698-A1 02-02-2006 Tomizuka et al. AR6* US-20060078992-A1 04-13-2006 Misawa et al. AS6* US-20060123490-A1 06-08-2006 Kakitani et al. AT6* US-20060011375-A1 01-19-2006 Sugimoto et al. AU6* US-20060185025-A1 08-17-2006 Oshimura et al. AV6* US-20060167043-A1 07-27-2006 Iwakubo et al. AW6 US-20060233902-A1 10-19-2006 Yajima et al. ** AX6* US-20060217426-A1 09-28-2006 Eto et al. AY6* US-20040073957-A1 04-15-2004 Tomizuka et al. AZ6* US-20040175814-A1 09-09-2004 Kato et al. AA7* US-20050032210-A1 02-10-2005 Sato et al. AC7* US-20020199213-A1 12-26-2002 Tomizuka et al.	<u> </u>				•	
AO6* US-20060041945-A1 02-23-2006 Robl et al. AP6* US-20060037093-A1 02-16-2006 Tomizuka et al. AQ6* US-20060026698-A1 02-02-2006 Tomizuka et al. AR6* US-20060078992-A1 04-13-2006 Misawa et al. AS6* US-20060123490-A1 06-08-2006 Kakitani et al. AT6* US-20060011375-A1 01-19-2006 Sugimoto et al. AU6* US-20060185025-A1 08-17-2006 Oshimura et al. AV6* US-20060167043-A1 07-27-2006 Iwakubo et al. AW6 US-20060233902-A1 10-19-2006 Yajima et al. ** AX6* US-20060217426-A1 09-28-2006 Eto et al. AY6* US-20040073957-A1 04-15-2004 Tomizuka et al. AZ6* US-20040175814-A1 09-09-2004 Kato et al. AX7* US-20050032210-A1 02-10-2005 Sato et al. AC7* US-20020199213-A1 12-26-2002 Tomizuka et al.					+-	- · · · ·
AP6* US-20060037093-A1 02-16-2006 Tomizuka et al. AQ6* US-20060026698-A1 02-02-2006 Tomizuka et al. AR6* US-20060078992-A1 04-13-2006 Misawa et al. AS6* US-20060123490-A1 06-08-2006 Kakitani et al. AT6* US-20060011375-A1 01-19-2006 Sugimoto et al. AU6* US-20060185025-A1 08-17-2006 Oshimura et al. AV6* US-20060167043-A1 07-27-2006 Iwakubo et al. AW6 US-20060233902-A1 10-19-2006 Yajima et al. ** AX6* US-20060217426-A1 09-28-2006 Eto et al. AY6* US-20040073957-A1 04-15-2004 Tomizuka et al. AZ6* US-20040175814-A1 09-09-2004 Kato et al. AX7* US-20050032210-A1 02-10-2005 Sato et al. AC7* US-20020199213-A1 12-26-2002 Tomizuka et al.						
AQ6* US-20060026698-A1 02-02-2006 Tomizuka et al. AR6* US-20060078992-A1 04-13-2006 Misawa et al. AS6* US-20060123490-A1 06-08-2006 Kakitani et al. AT6* US-20060011375-A1 01-19-2006 Sugimoto et al. AU6* US-20060185025-A1 08-17-2006 Oshimura et al. AV6* US-20060167043-A1 07-27-2006 Iwakubo et al. AW6 US-20060233902-A1 10-19-2006 Yajima et al. * AX6* US-20060217426-A1 09-28-2006 Eto et al. AY6* US-20040073957-A1 04-15-2004 Tomizuka et al. AZ6* US-20040175814-A1 09-09-2004 Kato et al. AA7* US-20040235162-A1 11-25-2004 Sato AB7* US-20050032210-A1 02-10-2005 Sato et al. AC7* US-20020199213-A1 12-26-2002 Tomizuka et al.	-					
AR6* US-2006078992-A1 04-13-2006 Misawa et al. AS6* US-20060123490-A1 06-08-2006 Kakitani et al. AT6* US-20060011375-A1 01-19-2006 Sugimoto et al. AU6* US-20060185025-A1 08-17-2006 Oshimura et al. AV6* US-20060167043-A1 07-27-2006 Iwakubo et al. AW6 US-20060233902-A1 10-19-2006 Yajima et al. ** AX6* US-20060217426-A1 09-28-2006 Eto et al. AY6* US-20040073957-A1 04-15-2004 Tomizuka et al. AZ6* US-20040175814-A1 09-09-2004 Kato et al. AA7* US-20040235162-A1 11-25-2004 Sato AB7* US-20050032210-A1 02-10-2005 Sato et al. AC7* US-20020199213-A1 12-26-2002 Tomizuka et al.						
AS6* US-20060123490-A1 06-08-2006 Kakitani et al. AT6* US-20060011375-A1 01-19-2006 Sugimoto et al. AU6* US-20060185025-A1 08-17-2006 Oshimura et al. AV6* US-20060167043-A1 07-27-2006 Iwakubo et al. AW6					<u> </u>	
AT6* US-20060011375-A1 01-19-2006 Sugimoto et al. AU6* US-20060185025-A1 08-17-2006 Oshimura et al. AV6* US-20060167043-A1 07-27-2006 Iwakubo et al. AW6 US-20060233902-A1 10-19-2006 Yajima et al. * AX6* US-20060217426-A1 09-28-2006 Eto et al. AY6* US-20040073957-A1 04-15-2004 Tomizuka et al. AZ6* US-20040175814-A1 09-09-2004 Kato et al. AA7* US-20040235162-A1 11-25-2004 Sato AB7* US-20050032210-A1 02-10-2005 Sato et al. AC7* US-20020199213-A1 12-26-2002 Tomizuka et al.	-					
AU6* US-20060185025-A1 08-17-2006 Oshimura et al. AV6* US-20060167043-A1 07-27-2006 Iwakubo et al. AW6 US-20060233902-A1 10-19-2006 Yajima et al. * AX6* US-20060217426-A1 09-28-2006 Eto et al. AY6* US-20040073957-A1 04-15-2004 Tomizuka et al. AZ6* US-20040175814-A1 09-09-2004 Kato et al. AA7* US-20040235162-A1 11-25-2004 Sato AB7* US-20050032210-A1 02-10-2005 Sato et al. AC7* US-20020199213-A1 12-26-2002 Tomizuka et al.						*:
AV6* US-20060167043-A1 07-27-2006 lwakubo et al. AW6 US-20060233902-A1 10-19-2006 Yajima et al. AX6* US-20060217426-A1 09-28-2006 Eto et al. AY6* US-20040073957-A1 04-15-2004 Tomizuka et al. AZ6* US-20040175814-A1 09-09-2004 Kato et al. AA7* US-20040235162-A1 11-25-2004 Sato AB7* US-20050032210-A1 02-10-2005 Sato et al. AC7* US-20020199213-A1 12-26-2002 Tomizuka et al.						
AW6 US-20060233902-A1 10-19-2006 Yajima et al. AX6* US-20060217426-A1 09-28-2006 Eto et al. AY6* US-20040073957-A1 04-15-2004 Tomizuka et al. AZ6* US-20040175814-A1 09-09-2004 Kato et al. AA7* US-20040235162-A1 11-25-2004 Sato AB7* US-20050032210-A1 02-10-2005 Sato et al. AC7* US-20020199213-A1 12-26-2002 Tomizuka et al.						
AX6* US-20060217426-A1 09-28-2006 Eto et al. AY6* US-20040073957-A1 04-15-2004 Tomizuka et al. AZ6* US-20040175814-A1 09-09-2004 Kato et al. AA7* US-20040235162-A1 11-25-2004 Sato AB7* US-20050032210-A1 02-10-2005 Sato et al. AC7* US-20020199213-A1 12-26-2002 Tomizuka et al.					+	
AY6* US-20040073957-A1 04-15-2004 Tomizuka et al. AZ6* US-20040175814-A1 09-09-2004 Kato et al. AA7* US-20040235162-A1 11-25-2004 Sato AB7* US-20050032210-A1 02-10-2005 Sato et al. AC7* US-20020199213-A1 12-26-2002 Tomizuka et al.	L	*				1
AZ6* US-20040175814-A1 09-09-2004 Kato et al.					 	
AA7* US-20040235162-A1 11-25-2004 Sato AB7* US-20050032210-A1 02-10-2005 Sato et al. AC7* US-20020199213-A1 12-26-2002 Tomizuka et al.						
AB7* US-20050032210-A1 02-10-2005 Sato et al. AC7* US-20020199213-A1 12-26-2002 Tomizuka et al.						
AC7* US-20020199213-A1 12-26-2002 Tomizuka et al.				11-25-2004	Sato	
		-				
AD7* US-6,914,158-A1 07-05-2005 Webber et al.						
		AD7⁺	US-6,914,158-A1	07-05-2005	Webber et al.	

Examiner	Date	
Signature	Considered	

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/809,089-Conf. #7653	
11	NFORMATION	1 DI	SCLOSURE	Filing Date	March 25, 2004	
S	TATEMENT I	3Y /	APPLICANT	First Named Inventor	Andrew R. MARKS	
				Art Unit	N/A	
	(Use as many sh	eets as	s necessary)	Examiner Name	Not Yet Assigned	
Sheet	5	of	9	Attorney Docket Number	0019240.00596US1	

AE7*	US-6,951,889-A1	10-04-2005	Hansen, Jr. et al.
AF7*	US-7,005,450-A1	02-28-2006	Durley et al.
AG7*	US-7,102,013-A1	09-05-2006	Webber et al.
AH7*	US-6,756,406-A1	06-29-2004	Durley et al.
Al7*	US-6,787,668-A1	09-07-2004	Pitzele et al.
AJ7*	US-6,828,456-A1	12-07-2004	Hansen, Jr. et al.
AK7*	US-6,852,753-A1	02-08-2005	Koeller et al.
AL7*	US-6,403,830-A1	06-11-2002	Webber et al.
AM7*	US-6,465,686-A1	10-15-2002	Grapperhaus et al.
AN7*	US-6,465,518-A1	10-15-2002	Hansen, Jr. et al.
AO7*	US-6,495,544-A1	12-17-2002	Hansen, Jr. et al.
		04-08-2003	Pitzele et al.
AQ7*	US-6,586,474-A1	07-01-2003	Webber et al.
		11-17-2005	Durley et al.
AS7*	US-20050070543-A1	03-31-2005	Stephenson
AT7*	US-20050113451-A1	05-26-2005	* · · · · · · · · · · · · · · · · · · ·
AU7*	US-20050165106-A1	07-28-2005	Webber et al.
AV7*	US-20040192584-A1	09-30-2004	McMahon et al.
AW7	US-20040186178-A1	09-23-2004	Webber et al.
*			
AX7*	US-20030199701-A1	10-23-2003	Webber et al.
AY7*	US-20030199482-A1	10-23-2003	Seibert et al.
AZ7*	US-20030195218-A1	10-16-2003	Koeller et al.
	AF7* AG7* AH7* AH7* AH7* AH7* AH7* AH7* AH7* AH		AF7* US-7,005,450-A1 02-28-2006 AG7* US-7,102,013-A1 09-05-2006 AH7* US-6,756,406-A1 06-29-2004 AI7* US-6,787,668-A1 09-07-2004 AJ7* US-6,828,456-A1 12-07-2004 AK7* US-6,852,753-A1 02-08-2005 AL7* US-6,403,830-A1 06-11-2002 AM7* US-6,465,686-A1 10-15-2002 AM7* US-6,465,518-A1 10-15-2002 AN7* US-6,465,518-A1 10-15-2002 AN7* US-6,495,544-A1 12-17-2002 AP7* US-6,545,170-A1 04-08-2003 AQ7* US-6,586,474-A1 07-01-2003 AR7* US-20050256199-A1 11-17-2005 AS7* US-20050113451-A1 05-26-2005 AU7* US-20050113451-A1 05-26-2005 AU7* US-20040192584-A1 09-33-2004 AW7 US-20040186178-A1 09-23-2004 AW7 US-20030199701-A1 10-23-2003 AY7* US-20030199701-A1 10-23-2003

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear					
	ВА	WO-99/16758	04-08-1999	Dr. Reddy's Research Foundation		\prod				
	ВВ	WO-98/45291	10-15-1998	Dr. Reddy's Research Foundation						
	ВС	EP-1743895	01-17-2007	Aetas Pharma Col., Ltd.		\Box				
	BD	EP-0467325	01-22-1992	Syntex (USA) Inc.						
	BE	WO-05/105793	11-10-2005	Aetas Pharma Co. Ltd						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. *Applicant's unique citation designation number (optional). *Z See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	CA	Hain, Jurgen et al. "Phosphorylation Modulates the Function of the Calcium Release Channel of Sarcoplasmic Reticulum from Cardiac Muscle." The Journal of Biological Chemistry, Vol. 270, No. 5, pp. 2074-2081. (February 3, 1995).	

Examiner	Date
Signature	Considered

Sub	ostitute for form 1449/PTO)		Complete if Known		
				Application Number	10/809,089-Conf. #7653	
11	NFORMATIO	N DIS	SCLOSURE	Filing Date	March 25, 2004	
S	TATEMENT	BY A	PPLICANT	First Named Inventor	Andrew R. MARKS	
				Art Unit	N/A	
	(Use as many s	heets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	6	of	9	Attorney Docket Number	0019240.00596US1	

СВ	Isselbacher, Kurt J. et al. "Harrison's Principles of Internal Medicine." 13th Edition, Vol. 1, pp. 1022-1024. (1994).	
CC	Kohno et al., "A New Cardioprotective Agent, JTV-519, Improves Defective Channel Gating of Ryanodine Receptor in Heart Failure." Am. J. Physiol Heart Circ. Physiol., Vol. 284, No. 3, pp. H1035-H1042. First published November 14, 2002. (March 2003)	
CD	Kumagai et al. "Antiarrhythmic Effects of JTV-519, a novel Cardioprotective Drug, on Atrial Fibrillation/Flutter in a Canine Sterile Pericarditis Model." J. Cardiovasc. Electrophysiol. Vol. 14, No. 8, pp. 880-884. (2003).	
CE	Szabo et al. "Synthesis and Transformations of 4,5-Dihydro-1,4-benzothiazepin-3(2H)-one Derivatives1,2)." Chemische Berichte., Vol. 119, No. 9, pp. 2904-2913. (1986).	
CF	Szabo, Janos et al., "Synthesis and Spectroscopic Investigations of 1,4-benzothiazepine derivatives." Can. J. Chem, Vol. 65, pp. 175-181. (1987).	
CG	Yano et al., "RyR-Bound FKBP12.6 and the Modulation." Journal Clinical Calcium, Vol. 11, No. 6, pp. 743-748. (June 2001).	
СН	Haut, Donahue, et al., "Annexin V Disruption Impairs Mechanically Induced Calcium Signaling in Osteoblastic Cells," Bone, Vol 35, No 3) pp. 656-63, (2004)	
CI	Ackerman, MJ, "Cardiac channelopathies: it's in the genes," Nat. Med., Vol. 10, pp. 463-4 (2004)	
CJ	Bangur, et al., "Mutational analysis of the D1/E1 core helices and the conserved N-terminal region of yeast transcription factor IIB (TFIIB): identification of an N-terminal mutant that stabilizes TATA-binding protein-TFIIB-DNA complexes," Mol. Cell Biol., Vol. 17, pp. 6784-93 (1997)	
СК	Brillantes, et al., "Developmental and tissue-specific regulation of rabbit skeletal and cardiac muscle calcium channels involved in excitation-contraction coupline, " Circ. Res., Vol. 75, pp. 503-10 (1994)	
CL	Brillantes, et al., "Differences in cardiac calcium release channel (ryanodine receptor) expression in myocardium from patients with end-state heart failure caused by ischemic versus dilated cardiomyopathy," Circ. Res., Vol. 71, pp. 18-26 (1992)	
СМ	Chatrath, et al., "Beta-blocker therapy failures in symptomatic probands with genotyped long-QT syndrome," Pediatr. Cardiol., Vol. 25, pp. 459-65 (2004)	
CN	Che, et al., "Reversal of P-glycoprotein mediated multidrug resistance by a newly synthesized 1,4-benzothiazipine derivative, JTV-519," Cancer Lett., Vol. 187, pp. 111-9 (2002)	
СО	Choi, et al., "Spectrum and frequency of cardiac channel defects in swimming-triggered arrhythmia syndromes," Circulation, Vol. 110, pp. 2119-24 (2004)	
СР	Choi, et al., "Sudden cardiac death and channelopathies: a review of implantable defibrillator therapy," Pediatr. Clin. North Am., Vol. 51, pp. 1289-1303 (2004)	
CQ	Farr, et al., "Sparking the failing heart," N. Engl. J. Med., Vol. 351, pp. 185-7 (2004)	
CR	Fitzgerald, et al., "Reduced ryanodine receptor content in isolated neonatal cardiomyocytes compared with the intact tissue," J. Mol. Cell, Cardiol., Vol. 26, pp. 1261-5 (1994)	
cs	Gillian, et al., "Analysis of expression of the human ryanodine receptor gene in malignant hyperthermia skeletal muscle tissue," Biochem. Soc. Trans., Vol. 19, pp. 46S (1991)	
СТ	Ikemoto, et al., "Regulation of calcium release by interdomain interaction within ryanodine receptors," Front Biosci., Vol. 7, pp. d671-683 (2002)	
СП	Kirsch, et al., "The roles of annexins and types II and X collagen in matrix vesicle-mediated mineralization of growth plate cartilage," J. Biol. Chem., Vol. 275, pp. 35577-83 (2000)	
cv	Kobrinsky, et al., "Expressed ryanodine receptor can substitute for the inositol 1,4,5-trisphosphate receptor in Xenopus laevis oocytes during progesterone-induced maturation," Dev. Biol., Vol. 172, pp. 531-40 (1995)	

Examiner	Date	
Signature	Considered Considered	

Sut	ostitute for form 1449/PTO			Complete if Known		
				Application Number	10/809,089-Conf. #7653	
l IN	NFORMATION	1 DI	SCLOSURE	Filing Date	March 25, 2004	
l s	TATEMENT B	3Y /	APPLICANT	First Named Inventor	Andrew R. MARKS	
				Art Unit	N/A	
	(Use as many sh	eets as	s necessary)	Examiner Name	Not Yet Assigned	
Sheet	7	of	9	Attorney Docket Number	0019240.00596US1	

		•						
	CW	Lehnart, et al., "Immunophilins and coupled gating of ryanodine receptors, "Curr. Top. Med. Chem., Vol. 3, pp. 1383-91 (2003)						
	СХ	Lehnart, et al., "Calstabin deficiency, ryanodine receptors, and sudden cardiac death, " Biochem. Biophys. Res. Commun., Vol. 322, pp. 1267-79 (2004)						
	CY Lesh, et al., "Anti-ryanodine receptor antibody binding sites in vascular and endo endothelium," Cir., Res., Vol. 72, pp. 481-8 (1993)							
	CZ	Marks, AR, "Calcium channels expressed in vascular smooth muscle," Circulation, Vol. 86, pp. III61-7 (1992)						
	CA1	Marks, AR, "Immunophilin modulation of calcium channel gating," Methods., Vol. 9, pp. 177-87 (1996)						
	CB1	Marks, AR, "Intracellular calcium-release channels: regulators of cell life and death," Am. J. Phsiol., Vol. 272, pp. H597-605 (1997)						
	CC1	Marks, et al., "Molecular cloning and characterization of the Ryanodine receptor/junctional channel complex cDNA from skeletal muscle sarcoplasmic reticulum," Proc. Natl. Acad. Sci. U.S.A., Vol. 86, pp. 8683-7 (1989)						
	CD1	Marks, et al., "Regulation of ryanodine receptors via macromolecular complexes: a novel role for leucine/isoleucine zippers," Tends Cardiovasc. Med., Vol. 12, pp. 166-70 (2002)						
	CE1	Marks, et al., "Surface topography analysis of the ryanodine receptor/junctional channel complex based on proteolysis sensitivity mapping," J. Biol. Chem., Vol. 265, pp. 13143-9 (1990)						
	CF1	Marks, et al., "The ryanodine receptor/junctional channel complex is regulated by growth factors in a myogenic cell line," J. Cell. Biol., Vol. 114, pp. 303-12, (1991)						
	CG1 Maron, et al., "Recommendations for physical activity and recreational sports participation f young patients with genetic cardiovascular diseases," Circulation, Vol., 109, pp. 2807-16 (2004)							
· 	CH1 McPhie, et al., "Structure of the hormone binding domain of human beta 1 thyroid horn nuclear receptor: is is an alpha/beta barrel?" Biochemistry, Vol. 32, pp. 7460-5 (1993)							
	CI1 Nakamura, et al., "Reversal of cisplatin resistance by the 1,4-benzothiazepine derivative, J7 519," Jpn. J. Cancer Res., Vol. 92, pp. 597-602 (2001)							
	CJ1	Ondrias, et al., "FKBP12 modulates gating of the ryanodine receptor/calcium release channel," Ann. N.Y. Acad. Sci., Vol. 853, pp. 149-56 (1998)						
	CK1	Ondrias, et al., "Single channel properties and calcium conductance of the cloned expressed ryanodine receptor/calcium-release channel, Soc. Gen. Physiol. Serv., Vol. 51, pp. 29-45 (1996)						
	CL1	Paul-Pletzer, et al., "Identification of a dantrolene-binding sequence on the skeletal muscle ryanodine receptor," J. Biol. Chem., Vol. 277, pp. 34918-23 (2002)						
	CM1	Rosemblit, et al., "Intracellular calcium release channel expression during embryogenesis," Dev. Biol., Vol. 206, pp. 163-77 (1999)						
	CN1	Shtifman, et al., "Interdomain interactions within ryanodine receptors regulate Ca2+ spark frequency in skeletal muscle," J. Gen. Physiol., Vol. 119, pp. 15-31 (2002)						
	CO1 Tester, et al., "Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing," Heart Rhythm. Vol. 2, pp. 507-17 (2005)							
	CP1	Tester, et al., "Targeted mutational analysis of the RyR2-encoded cardiac ryanodine receptor in sudden unexplained death: a molecular authopsy of 40 medical examiner/coroner's cases," May Clin. Proc., Vol. 79, pp. 1380-4 (2004)						
	CQ1	Timerman, et al., "The ryanodine receptor from canine heart sacroplasmic reticulum is associated with a novel FK-506 binding protein," Biochem. Biophys. Res. Commun., Vol. 198, pp. 701-6 (1994)						
Examiner Signature	•	Date Considered						
6090211								

Sut	bstitute for form 1449/PTO			Complete if Known		
				Application Number	10/809,089-Conf. #7653	
11	NFORMATION	1 DI	SCLOSURE	Filing Date	March 25, 2004	
S	TATEMENT B	3Y /	APPLICANT	First Named Inventor	Andrew R. MARKS	
				Art Unit	N/A	
	(Use as many sh	eets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	8	of	9	Attorney Docket Number	0019240.00596US1	

i	CR1	Tipton, et al., "My child just fainted: no big deal or sudden-death warning?" Emerg. Med. Serv., Vol. 33, pp. 41-5 (2004)					
	CS1	Wang, et al., "Retinoic acid stimulates annexin-mediated growth plate chondrocyte mineralization," J. Cell Biol., Vol. 157, pp. 1061-9 (2002)					
	CT1	Wang, W., et al., "Annexin-mediated Ca2+ influx regulates growth plate chondrocyte maturation and apoptosis," J. Biol Chem, Vol. 278, pp. 3762-9 (2003)					
	CU1	Ward, et al., "Defects in ryanodine receptor calcium release in skeletal muscle from post-myocardial infarct rats, "Faseb J., Vol, 17, pp. 1517-9 (2003)					
	CV1	Wehrens, et al., "Altered function and regulation of cardiac ryanodine receptors in cardiac disease, "Trends Biochem. Sci., Vol. 28, pp. 671-8 (2003)					
	CW1	Wehrens, et al., "Myocardial disease in failing hearts: defective excitation-contraction coupling, "Cold Spring Harb. Symp. Quant. Biol., Vol. 67, pp. 533-41 (2002)					
	CX1	Yamamoto, et al., "Ca2+-dependent dual function of peptice C. The peptide corresponding to the Glu724-Pro760 region (the so-called determinant of excitation-contraction coupling) of the dihydropyridine receptor alpha 1 subunit II-III loop," J. Biol. Chem., Vol. 277, pp. 993-1001 (2002)					
	CY1	Yamamoto, et al., "Peptide probe study of the critical regulatory domain of the cardiac ryanodine receptor," Biochem, Biophys. Res. Commun., Vol. 291, pp. 1102-8 (2002)					
	CZ1	Yamamoto, et al., "Spectroscopic monitoring of local conformational changes during the intramolecular domain-domain interaction of the ryanodine receptor," Biochemistry, Vol, 41, pp. 1492-501 (2002)					
	CA2	Marks, AR, "Arrhythmias of the heart: beyond ion channels," Nat. Medicine, Vol. 9, pp. 263-4, (2003)					
	CB2	Marks, AR, "Calcium and the heart: a question of life and death," J. Clin. Investigation, Vol. 111, pp. 597-600, (2003)					
	CC2	Manzur, et al., "A severe clinical and pathological variant of central core disease with possible autosomal recessive inheritance," Neur. Disorders, Vol. 8, pp. 467-473 (1998)					
	CD2	Swan, et al., "Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations," J. of Card. Electrophysiology, Vol. 16, No. 2, pp. 162-6, (2005)					
	CE2	Culligan, et al., "Drastic reduction of calsequestrin-like proteins and impaired calcium binding in dystrophic mdx muscle," J. Appl. Physiol., Vol. 92, pp. 435-445 (2002)					
	CF2	Dorian, P., "Antiarrhythmic action of beta-blockers: potential mechanisms," J. Cardiovasc. Pharmacol. Therapeut., Vol. 10, pp. S15-S22 (2005)					
	CG2	Morita, et al., "Ca channel blocking activity of JTV-519, a novel protective drug to cytotoxicity," Neuroscience Research, Vol. 31, Supp. 1, p. S65 (1998)					
	CH2	Ishii, et al., "JTV-519, a new cardioprotective drug, and cariporide, synergistically improved post-ischemic contractile recovery in rat," Journal of Molecular and Cellular Cardiology, Vol. 35, Issue 6, p A29 (2002)					
	CI2	Lee, et al., "Sudden unexplained death: evaluation of those left behind," The Lancet, Vol. 362, pp. 1429-1431 (2003)					
	CJ2	Behr, et al., "Cardiological assessment of first-degree relatives in sudden arrhythmic death syndrome," The Lancet, Vol. 362, 1457-59 (2003)					
	CK2	Yamamoto, et al., "T-tubule depolarization-induced local events in the ryanodine receptor, as monitored with the fluorescent conformational probe incorporated by mediation of peptide A," J. Biol. Chem. Vol. 277, pp. 984-92 (2002)					
	CL2						
Examiner Signature		Date Considered					
0000044							

Sut	ostitute for form 1449/PTO	-		Complete if Known	
				Application Number	10/809,089-Conf. #7653
11	NFORMATION	1 DI	SCLOSURE	Filing Date	March 25, 2004
l s	TATEMENT I	3Y <i>i</i>	APPLICANT	First Named Inventor	Andrew R. MARKS
			,	Art Unit	N/A
	(Use as many sh	eets a	s necessary)	Examiner Name	Not Yet Assigned
Sheet	9	of	9	Attorney Docket Number	0019240.00596US1

CM	Echt et al., "Mortality and morbidity in patients receiving encainide, flecainide, or placebo," The Cardiac Arrhythmia Suppression Trial, N. Engl. J. Med., Vol 324, pp. 781-788. (1991)	
CN		-
co	Shiroshita-Takeshita et al., "Atrial fibrillation: basic mechanisms, remodeling and triggers," J. Interv. Card. Electrophysiol, Vol. 13, pp. 181-193. (2005)	
СР	Stevenson, W.G. et al., "Sudden death prevention in patients with advanced ventricular dysfunction," Circulation, Vol. 88, pp. 2953-2961. 1993	
ca	Wilde et al., "Ion Channels, the QT interval, and arrhythmias," Pacing Clin Electrophysiol, Vol. 20, pp. 2048-2051. 1997	
CR	Special Report "Preliminary Report: Effect of Encainide and Flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infraction," The New England Jour. of Med., Vol 321, No 6, pp. 406-412. (1989)	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{&#}x27;Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Application No. (if known): 10/809,089

Attorney Docket No.: 0019240.00596US1

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV 901256316 US in an envelope addressed to:

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on 3507

Janen	1 Love				
Signature					
Jane M. Love, F	Ph.D.				
Typed or printed name of person signing Certificate					
42,812 .	(212) 230-8800				
Registration Number, if applicable	Telephone Number				

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (283 References) (9 pages) Supplemental Information Disclosure Statement (2 pages)

Transmittal (1 page)

Postcard